Treatment with the Arginase Inhibitor Nw-hydroxy-nor-L-arginine Restores Endothelial Function in Rat Adjuvant-induced Arthritis

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2012 Jun 1

PMID 22647483

Citations 17

Authors

Clement Prati

Alain Berthelot

Bernadette Kantelip

Daniel Wendling

Celine Demougeot

Affiliations

Soon will be listed here.

Abstract

Introduction: Endothelial dysfunction (ED) participates to atherogenesis associated to rheumatoid arthritis. We recently reported increased arginase activity/expression in vessels from adjuvant-induced arthritis (AIA) rats. In the present study, we investigated the effects of a curative treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine (nor-NOHA) on vascular dysfunction in AIA rats.

Methods: AIA rats were treated with nor-NOHA (40 mg/kg/d, ip) for 21 days after the onset of arthritis. A group of untreated AIA rats and a group of healthy rats served as controls. ED was assessed by the vasodilatory effect of acetylcholine (Ach) on aortic rings. The role of superoxide anions, prostanoids, endothelium-derived hyperpolarizing factor (EDHF) and nitric oxide synthase (NOS) pathway was studied. Plasma levels of IL-6 and vascular endothelial growth factor (VEGF) were determined by ELISA kits. Arthritis severity was estimated by a clinical, radiological and histological analysis.

Results: Nor-NOHA treatment fully restored the aortic response to Ach to that of healthy controls. The results showed that this beneficial effect is mediated by an increase in NOS activity and EDHF and reduced superoxide anion production as well as a decrease in the activity of cyclooxygenase (COX)-2, thromboxane and prostacyclins synthases. In addition, nor-NOHA decreased IL-6 and VEGF plasma levels in AIA rats. By contrast, the treatment did not modify arthritis severity in AIA rats.

Conclusions: The treatment with an arginase inhibitor has a potent effect on ED in AIA independently of the severity of the disease. Our results suggest that this new pharmacological approach has the potential as a novel add-on therapy in the treatment of RA.

Citing Articles

The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer.

Azzam H, El-Derany M, Wahdan S, Faheim R, Helal G, El-Demerdash E Hum Cell. 2023; 36(6):1877-1886.

PMID: 37646973 PMC: 10587280. DOI: 10.1007/s13577-023-00977-5.

Arginine Dysregulation and Myocardial Dysfunction in a Mouse Model and Children with Chronic Kidney Disease.

Reyes L, Winterberg P, George R, Kelleman M, Harris F, Jo H Nutrients. 2023; 15(9.

PMID: 37432321 PMC: 10181438. DOI: 10.3390/nu15092162.

Ischemic Heart Disease and Rheumatoid Arthritis-Two Conditions, the Same Background.

Rezus E, Macovei L, Burlui A, Cardoneanu A, Rezus C Life (Basel). 2021; 11(10).

PMID: 34685413 PMC: 8537055. DOI: 10.3390/life11101042.

Mammalian Arginase Inhibitory Activity of Methanolic Extracts and Isolated Compounds from Species.

Arraki K, Totoson P, Decendit A, Zedet A, Maroilley J, Badoc A Molecules. 2021; 26(6).

PMID: 33803532 PMC: 8002983. DOI: 10.3390/molecules26061694.

Amino Acid Metabolism in Rheumatoid Arthritis: Friend or Foe?.

Panfili E, Gerli R, Grohmann U, Pallotta M Biomolecules. 2020; 10(9).

PMID: 32899743 PMC: 7563518. DOI: 10.3390/biom10091280.

References

Philis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, Witztum J . Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol. 1995; 15(3):367-76. DOI: 10.1161/01.atv.15.3.367. View

Largo R, Sanchez-Pernaute O, Marcos M, Moreno-Rubio J, Aparicio C, Granado R . Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: a novel model of atherosclerosis associated with chronic inflammation. Arthritis Rheum. 2008; 58(9):2723-34. DOI: 10.1002/art.23765. View

Felmeden D, Blann A, Lip G . Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J. 2003; 24(7):586-603. DOI: 10.1016/s0195-668x(02)00635-8. View

Lim H, Lim H, Ryoo S, Benjo A, Shuleri K, Miriel V . Mitochondrial arginase II constrains endothelial NOS-3 activity. Am J Physiol Heart Circ Physiol. 2007; 293(6):H3317-24. DOI: 10.1152/ajpheart.00700.2007. View

Egan C, Lockhart J, Ferrell W . Pathophysiology of vascular dysfunction in a rat model of chronic joint inflammation. J Physiol. 2004; 557(Pt 2):635-43. PMC: 1665086. DOI: 10.1113/jphysiol.2004.062984. View

Corraliza I, Moncada S . Increased expression of arginase II in patients with different forms of arthritis. Implications of the regulation of nitric oxide. J Rheumatol. 2002; 29(11):2261-5. View

Topal G, Topal J, Brunet A, Walch L, Boucher J, David-Dufilho M . Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells. J Pharmacol Exp Ther. 2006; 318(3):1368-74. DOI: 10.1124/jpet.106.103747. View

Buga G, Singh R, Pervin S, Rogers N, Schmitz D, Jenkinson C . Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol. 1996; 271(5 Pt 2):H1988-98. DOI: 10.1152/ajpheart.1996.271.5.H1988. View

Kinne R, Schmidt-Weber C, Hoppe R, Buchner E, Palombo-Kinne E, Nurnberg E . Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum. 1995; 38(12):1777-90. DOI: 10.1002/art.1780381211. View

10.

Nozaki K, Goto H, Nakagawa T, Hikiami H, Koizumi K, Shibahara N . Effects of keishibukuryogan on vascular function in adjuvant-induced arthritis rats. Biol Pharm Bull. 2007; 30(6):1042-7. DOI: 10.1248/bpb.30.1042. View

11.

Syngle A, Vohra K, Kaur L, Sharma S . Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scand J Rheumatol. 2008; 38(1):15-22. DOI: 10.1080/03009740802279709. View

12.

Cai X, Wong Y, Zhou H, Xie Y, Liu Z, Jiang Z . The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis. Naunyn Schmiedebergs Arch Pharmacol. 2006; 373(2):140-7. DOI: 10.1007/s00210-006-0062-5. View

13.

Santhanam L, Christianson D, Nyhan D, Berkowitz D . Arginase and vascular aging. J Appl Physiol (1985). 2008; 105(5):1632-42. PMC: 2584835. DOI: 10.1152/japplphysiol.90627.2008. View

14.

Edwards G, Dora K, Gardener M, Garland C, Weston A . K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998; 396(6708):269-72. DOI: 10.1038/24388. View

15.

Haruna Y, Morita Y, Komai N, Yada T, Sakuta T, Tomita N . Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis Rheum. 2006; 54(6):1847-55. DOI: 10.1002/art.21891. View

16.

Ming X, Barandier C, Viswambharan H, Kwak B, Mach F, Mazzolai L . Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation. 2004; 110(24):3708-14. DOI: 10.1161/01.CIR.0000142867.26182.32. View

17.

Carter J, Lubahn C, Lorton D, Osredkar T, Der T, Schaller J . Adjuvant-induced arthritis induces c-Fos chronically in neurons in the hippocampus. J Neuroimmunol. 2010; 230(1-2):85-94. DOI: 10.1016/j.jneuroim.2010.09.005. View

18.

Ulker S, Onal A, Hatip F, Surucu A, Alkanat M, Kosay S . Effect of nabumetone treatment on vascular responses of the thoracic aorta in rat experimental arthritis. Pharmacology. 2000; 60(3):136-42. DOI: 10.1159/000028358. View

19.

Flammer A, Luscher T . Human endothelial dysfunction: EDRFs. Pflugers Arch. 2010; 459(6):1005-13. DOI: 10.1007/s00424-010-0822-4. View

20.

Huang L, Chang K, Chen C, Liu H . Arginase levels are increased in patients with rheumatoid arthritis. Kaohsiung J Med Sci. 2001; 17(7):358-63. View